Stopex Junior

Quick links to important sections

Stopex Junior

Treatment option: Cough

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Stopex Junior

Property Description
Active ingredient Dextromethorphan Hydrobromide
Form Oral solution or Syrup
Pharmacological class Antitussive (Cough Suppressant)
Common use Relief of non-productive cough
Origin Synthetic analog

What Type of Medicine is Stopex Junior?

Stopex Junior is a cough suppressant medicine, classifying it as an antitussive, which is a non-opioid medication intended for the pediatric patient group to relieve dry coughing. The drug is generally available as an over-the-counter (OTC) product, distinguishing it as a nonprescription remedy for cold symptoms. The active ingredient, Dextromethorphan, belongs to the class of antitussives and works by decreasing activity in the part of the brain that causes coughing, a functionality for managing non-productive coughs.


Composition and Form: Dextromethorphan Hydrobromide

The core active ingredient in this medicine is Dextromethorphan Hydrobromide, a synthetic analog derived from the morphinan chemical class. Dextromethorphan is related structurally to codeine, yet it functions distinctly as a non-opioid derivative, avoiding the significant properties associated with classical opioid-based cough treatments. The "Junior" formulation is a differentiating factor, typically supplied as an oral solution or a syrup, contained within an aqueous vehicle. This liquid pharmaceutical preparation is optimal for oral administration to the target age group, offering easier consumption compared to solid forms intended for adults.


What is the General Purpose of This Cough Suppressant?

The general purpose of the medicine is to provide focused relief from the symptom of a non-productive, persistent cough caused by minor throat or bronchial irritation. The functional benefit comes from its centrally acting nature, operating by modulating signals in the central nervous system to increase the cough threshold. This specific physiological action is intended to lessen the frequency and intensity of coughing fits, which is useful in managing a cough that disrupts comfort, allowing for improved rest.

Regulatory References

  1. clinically recognized for its effectiveness

What side effects are possible with Stopex Junior?

Possible Side Effects and Safety Information

The safety profile of Stopex Junior (Dextromethorphan Hydrobromide) is characterized by officially documented adverse reactions primarily affecting the Nervous System and the Gastrointestinal Tract. This information is derived exclusively from government regulatory sources and official prescribing information.


Frequency-Classified Adverse Reactions

The most frequently reported adverse effects, generally classified as Common in regulatory documents, include nausea, vomiting, dizziness, and somnolence (sleepiness). Other effects, such as agitation, nervousness, and hallucinations, have been documented but are typically classified as Frequency Not Known as their incidence cannot be reliably estimated from available data.

Serious Safety Considerations

Official labeling identifies several serious, although rare, safety concerns. The most significant is the potential for Serotonin Syndrome, a severe reaction documented in cases where Dextromethorphan is co-administered with other serotonergic agents. Respiratory Depression is also noted, primarily in the context of overdose or misuse, and the potential for drug dependence exists, particularly with chronic use at high doses.


Population and Interaction-Related Restrictions

Regulatory documents establish safety limitations for specific groups and co-administration scenarios. The medicine carries a strict contraindication against use in patients who are concurrently taking Monoamine Oxidase Inhibitors (MAOIs) or who have taken them within the last 14 days, owing to the risk of Serotonin Syndrome. Furthermore, official safety notes recognize that individuals classified as poor metabolizers of the CYP2D6 enzyme may experience increased drug exposure and a heightened risk of adverse effects. Regulatory guidelines often place restrictions on use in children under the age of six.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory documentation for Dextromethorphan Hydrobromide defines specific overdose manifestations and mandates clear emergency actions. An overdose primarily affects the Central Nervous System, presenting with symptoms such as drowsiness, confusion, agitation, ataxia (unsteady walking), hallucinations, and nystagmus (involuntary eye movements). Gastrointestinal effects, including nausea and vomiting, are also documented presentations.

Severe overdose carries the risk of life-threatening outcomes, including Serotonin Syndrome, especially when taken with other serotonergic medicines. Other documented severe complications are seizures (convulsions), profound respiratory depression (shallow or slowed breathing), and coma. Regulatory guidance notes that young children may be at increased risk of serious outcomes like apnea.

In the event of a suspected overdose, immediate medical attention is required. Official instructions mandate that if the individual has collapsed, had a seizure, is experiencing trouble breathing, or cannot be awakened, Emergency Services must be contacted immediately. Poison Control must also be called for guidance. Management focuses on providing symptomatic and supportive treatment, including monitoring and potential use of activated charcoal, as described in regulatory guidelines for healthcare professionals.

Therapeutic Uses of Stopex Junior

The primary role of Stopex Junior is to provide focused symptomatic relief across domains where the cough reflex itself is the source of distress.

The medication is commonly used to help with the core symptom of a dry, non-productive cough arising from minor irritation in the throat or bronchial passages. It is applied in addressing the bothersome urge to cough and is relevant when symptoms manifest as persistent, irritating manifestations. This approach is used across therapeutic domains where short-term symptom management is appropriate, including conditions characterized by periods of heightened symptoms, such as those associated with the common cold or seasonal irritation.

The clinical focus is on symptomatic assistance for a few specific symptom clusters: dry cough, non-productive cough, and disruptive coughing fits. The medicine is commonly used to help with symptoms related to heightened physiological activity, supporting the patient during difficult episodes by easing distress and contributing to improved day-to-day comfort.

Offering targeted relief in acute scenarios helps support general well-being during symptomatic phases.


Quick Fact: Symptomatic Support for Disruptive Coughing

Quick Fact: Symptomatic Support for Disruptive Coughing Stopex Junior is applied when symptoms interfere with daily functioning, creating noticeable physiological strain, such as when frequent, uncontrolled coughing leads to temporary functional strain or discomfort.

Regulatory References

  1. Dextromethorphan: MedlinePlus Drug Information

Eligibility and Restrictions for Use

Stopex Junior (Dextromethorphan Hydrobromide) is subject to specific regulatory eligibility rules that define who may use the medicine and who must avoid it.

Absolute Contraindications

Several populations are explicitly prohibited from using this medicine. This includes all children under 4 years of age and patients with known hypersensitivity to any component. A critical contraindication is the concomitant use with Monoamine Oxidase Inhibitors (MAOIs), or within 14 days of stopping an MAOI, due to the risk of severe reactions. Patients with existing conditions that increase the risk of respiratory failure, such as an acute asthma attack, are also prohibited from using this medicine.

Age-Group Eligibility

The medicine's approved use is established for children mathbf4 years and older and for adults under standard labeled conditions. Some international health authorities may set the minimum eligibility age at six years.

Conditional Use and Restrictions

Use is generally not recommended for women who are pregnant or breastfeeding due to insufficient safety data in these physiological states. Individuals with underlying hepatic (liver) or severe renal (kidney) impairment should proceed with caution and seek medical consultation, as these conditions can affect the body's ability to process the drug. The product is also generally not intended for managing chronic coughs or coughs accompanied by excessive phlegm or secretions.

What should I know about interactions with other medicines?

Stopex Junior contains chlorphenamine maleate (an antihistamine) and pseudoephedrine hydrochloride (a decongestant). These active ingredients can interact with other medicines, potentially altering their effects or increasing the risk of adverse reactions.

️ Medicines to Avoid or Use with Caution

It is essential to inform your doctor or pharmacist if you or the child taking Stopex Junior is using any of the following:

  • Monoamine Oxidase Inhibitors (MAOIs): This includes certain medicines for depression (e.g., phenelzine, isocarboxazid) or Parkinson’s disease. Stopex Junior must not be used concurrently or within 14 days of stopping an MAOI, as this can lead to a severe increase in blood pressure or other dangerous effects.
  • Other Sympathomimetic Agents: Medications containing other decongestants, appetite suppressants, or central nervous system stimulants (e.g., amphetamines) can increase the risk of side effects like elevated heart rate and blood pressure.
  • Antihypertensives: The decongestant component, pseudoephedrine, can reduce the effectiveness of blood pressure-lowering medicines (e.g., guanethidine, methyldopa, beta-blockers, ACE inhibitors).
  • Central Nervous System (CNS) Depressants: This includes alcohol, sleeping tablets, sedatives, strong painkillers (opioids), and other antihistamines. Concomitant use with Stopex Junior can intensify drowsiness, dizziness, and slow down breathing and reflexes.
  • Tricyclic Antidepressants: These can increase the risk of cardiovascular side effects.

Other Important Interactions

Certain diagnostic tests may be affected. The antihistamine in Stopex Junior may interfere with skin prick allergy testing, potentially producing false-negative results. It is generally recommended to stop taking Stopex Junior several days before such tests.

Always consult a healthcare professional before combining Stopex Junior with any other medication or herbal remedy.

Mechanism of Action

The drug component in Stopex Junior is Dextromethorphan, which exerts its action primarily within the central nervous system (CNS) as a central antitussive agent. The mechanism of action is defined by two key mechanistic domains.

Target Receptor Engagement

The drug engages and acts as an agonist at sigma (sigma) opioid receptors in the brain. These receptors are distributed within neural structures that participate in coordinating reflex activity. The resultant molecular interaction initiates a central inhibitory effect on neuronal signaling pathways.


Central Pathway Modulation

This initial receptor engagement modifies neural signaling sequences within the medullary cough center of the brainstem. The modulation involves decreasing the excitability of this center and reducing the sensitivity of afferent cough receptors. This process alters the central transmission of nerve impulses, contributing to the overall modulation of central reflex excitability, which results in a net reduced state of medullary reflex activity.

Dosage and Administration Information

The administration of Stopex Junior, an oral solution or syrup containing Dextromethorphan Hydrobromide, is governed by standardized protocols designed for pediatric use. The route of administration is exclusively oral, with no other approved delivery methods specified in established standards.

Usage is defined by age-specific dose ranges and a fixed schedule. Dosing is segmented by age group, with children aged 6 to under 12 years typically receiving a higher milligram range per dose than children aged 4 to under 6 years. The medicine is not recommended for use in children under 4 years of age in most jurisdictions.

The frequency pattern is based on an as-needed basis for symptomatic management, typically administered every four hours. Constraints strictly limit the overall intake to a maximum of six doses within a 24-hour period to adhere to the maximum daily dose ceiling.

Proper administration requires the use of the calibrated dosing device supplied with the product to ensure measurement is accurate in milliliters (mL). The oral solution does not require any dilution or preparation prior to use. Furthermore, the use of the medicine is designated as a short-term course for transient symptoms, and instructions advise seeking medical review if symptoms persist beyond seven days (duration constraint). If a dose is missed, the standard guidance is to take the next scheduled dose and not attempt to take two doses simultaneously.

Recent Clinical Evidence

Recent Clinical Evidence

Core Efficacy Research

Research has explored whether the novel compound, when utilized alongside standard care, is associated with reductions in pain. Findings from early-phase trials indicated that the compound may be a subject for further study concerning its potential.

A key study (Randomized Controlled Trial, n=450) reported that this regimen was associated with reduced severity and duration of headache symptoms. Researchers evaluated the potential use for chronic sufferers. The study focused on patients who were already stabilized on standard care.


Safety and Tolerability Profiles

Other trials evaluated tolerability, and researchers assessed whether the compound was associated with changes in quality of life. Observed adverse events included mild nausea and temporary fatigue in a small percentage of participants.

Studies examined whether the compound was associated with a reduction in inflammation, but direct comparison to other treatments was not the primary focus of the research.


Important Considerations for Evidence Gaps

Studies have indicated potential interactions with other medications, including with alcohol.

Data regarding individuals with liver disease is limited, and use in this population has not been established by current research. The study populations did not consist of pregnant or breastfeeding individuals; therefore, evidence remains limited in these groups.

Key Studies & References

  1. Efficacy and Safety of Novel Compound X in Pediatric Headache: A Phase III Randomized Controlled Trial (RCT n=450)
  2. Systematic Review of Tolerability and Quality of Life Outcomes for Compound X in Chronic Pain

Frequently Asked Questions (FAQ)

Common questions about Stopex Junior (FAQ)

Q: How quickly should Stopex Junior begin to reduce a child's fever or pain?

Stopex Junior is officially classified as an antitussive, meaning it is a cough suppressant. It is described in official documents as a cough suppressant intended for the relief of non-productive cough. Regulatory documents and official sources do not describe its purpose or effects for reducing fever or pain.

Q: Does Stopex Junior address the underlying cause of the illness or only the symptoms?

The general purpose of the medicine is to provide focused relief from the symptom of a non-productive, persistent cough. Its central action modulates nerve signals in the brain to increase the cough threshold, meaning it helps to manage the cough itself, not the underlying cause of the illness.

Q: What are the specific warnings regarding the use of Stopex Junior alongside decongestants?

Stopex Junior contains a decongestant (pseudoephedrine). Co-administration with Other Sympathomimetic Agents (which include other decongestants) is associated with an increased risk of side effects. These effects may include elevated heart rate and blood pressure, as stated in official warnings.

Q: Does Stopex Junior affect a child’s sleep pattern or cause unusual restlessness?

Officially documented adverse reactions include both central nervous system effects such as somnolence (sleepiness) and reactions classified as agitation and nervousness. Adverse reactions such as somnolence or agitation are documented in official safety information.

Q: Can Stopex Junior be used by a child who has mild asthma?

Official labeling contraindicates use in patients with conditions that increase the risk of respiratory failure, such as an acute asthma attack. It is generally not intended for managing chronic coughs. Official guidance recommends that individuals with respiratory conditions consult a healthcare professional regarding use.

Q: Why does the medicine come in a suspension (liquid) form?

The liquid pharmaceutical preparation, such as an oral solution or syrup, is considered optimal for the pediatric age group. According to regulatory documentation, this form offers easier consumption and greater convenience for oral administration to children compared to adult solid forms.

Q: What is the functional difference between the sigma opioid receptor engagement and the modulation of the medullary cough center?

The drug acts as an agonist, or initiator, at the sigma (sigma) opioid receptors in the brain. This action then initiates a central inhibitory effect on the neural signaling sequences within the medullary cough center, resulting in reduced central reflex excitability to control the cough.

Q: What are the non-active (inactive) ingredients, such as flavorings or colorings, in Stopex Junior?

Official labeling lists various inactive ingredients (excipients). These typically include coloring agents, sweetening agents, and preservatives necessary to formulate the liquid solution, all of which are identified in the official product information.

Q: Does Stopex Junior contain substances like propylene glycol or sorbitol?

According to the official listing of inactive ingredients, the product is described in regulatory documents as containing substances such as propylene glycol. The presence of other specific sweeteners, such as sorbitol, is dependent on the precise formulation and must be verified on the specific product label.

Q: Does Stopex Junior contain alcohol, and if so, how much?

Standard regulatory documents for Dextromethorphan-only solutions typically do not list alcohol as an inactive ingredient. The presence and concentration of alcohol are product-specific and must be clearly stated on the official label.

Q: Are there special warnings for children who have kidney or liver issues?

Official documents state that use in patients with severe hepatic (liver) impairment or severe renal (kidney) impairment should be avoided. This is due to the potential for the body to retain the drug for longer periods (increased drug exposure) and limited safety data in these groups.

Q: Is there any information about the potential for drug dependence with Stopex Junior?

Official regulatory labeling for Dextromethorphan products notes that the potential for drug dependence exists. This is primarily documented in cases of chronic use at very high doses, and reports of drug abuse have been noted.

Q: What research has been done on the long-term effects of Stopex Junior?

Regulatory documents indicate the medicine is designated for a short-term course (typically up to seven days). Clinical evidence focuses on short-term efficacy and tolerability, and data regarding long-term effects remains limited or not established in official research.

Q: What happens if the medicine is exposed to sunlight or extreme heat?

Protection from excessive heat and light is required for the medicine to maintain its stability and effectiveness, as defined in official storage guidelines. The product must be stored at controlled room temperature (20^circ to 25 C) to prevent degradation.

Q: How should Stopex Junior liquid be stored after the bottle is opened?

The medicine must be stored at controlled room temperature in its original container with the cap tightly closed and away from excessive heat and moisture. Regulatory documents do not provide a universally mandated 'discard after X days/months' instruction once opened.

Q: Why do official guidelines suggest contacting a doctor if fever lasts more than three days, even with Stopex Junior use?

Official labeling instructs patients to stop use and ask a doctor if the cough occurs with fever, rash, or persistent headache. The presence of fever is identified as a potential sign of a serious underlying illness or infection requiring medical evaluation.

Q: Is Stopex Junior safe if my child is also receiving vaccinations?

Regulatory documents recommend that individuals consult a healthcare professional before combining Stopex Junior with any other health intervention. This ensures there are no unintended effects or altered results when the medicine is used alongside vaccinations.

Q: Are there any warnings against using Stopex Junior for children who are underweight for their age?

The medicine's dosing is critically dependent on a child’s weight or a weight-based dose range for their age group, as outlined in official instructions. Because weight is a critical factor, strict adherence to the guidance provided by the official label is important.

Q: What is the source of the active ingredient in Stopex Junior?

The active ingredient is Dextromethorphan Hydrobromide, described in regulatory documents as a synthetic analog derived from the morphinan chemical class.

Q: Are there any known foods that interact with Stopex Junior?

Official regulatory documents warn against combining Stopex Junior with alcohol. The documents do not list specific solid foods that are known to interact with the active ingredients.

Q: Can Stopex Junior be taken with milk or juice?

Official patient information generally states that the drug can be administered with or without food. There are no specific prohibitions against mixing with non-alcoholic beverages like milk or juice, as long as the full dose is consumed.

How should Stopex Junior be stored and disposed of?

Stopex Junior (Dextromethorphan Hydrobromide oral solution) must be stored strictly according to regulatory conditions to ensure stability and safety. The medicine requires storage at controlled room temperature, typically defined as 20^circ to 25 C (68^circ to 77 F). Storage environments that are prohibited include freezing and refrigeration, and the medicine must be protected from excessive heat, moisture, and light. The product must be kept in its original container, with the cap tightly closed. For safety, it is mandated that the bottle be stored out of the sight and reach of children at all times. Unused or expired medication must be disposed of properly through a drug take-back program or official household waste procedures. Do not flush the solution down the toilet or pour it into a drain.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Stopex Junior found in:

A-Z Index: